Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neurodegenerative Diseases

Translational Research of the Nervous System

     Submit Your Manuscript
     Login for Returning Authors
     Login for Reviewers
     Editor Login

Guidelines for Authors
www.karger.com/neurodis_guidelines

Introduction
Submission
Conditions
Plagiarism Policy
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Supplementary Material
Drugs
Abbreviations
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Page Charges
E-Pub First
Proofs
Reprints


Introduction

Neurodegenerative Diseases is a multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington disease and related neurological and psychiatric disorders.

Neurodegenerative Diseases will accept high-quality papers in the form of either short reports (less than 5 pages) or articles (6-12 pages) from a broad spectrum of scientific research areas ranging from molecular and cell biology to neuroscience, pharmacology, genetics and clinical sciences.



Submission

Only original papers written in English are considered and should be submitted online.

Should you experience any problems with your submission, please contact:

Esther Bettiol
Editorial Office 'Neurodegenerative Diseases'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434
ndd@karger.com

Articles should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated. They do not normally exceed 6 printed pages including all figures, tables and references.

Brief Communications to Neurodegenerative Diseases are short reports of original research and are intended to provide a rapid means of reporting new findings of sufficient importance. They do not normally exceed 2 printed pages including an abstract, essential references and not more than 3 tables or figures.

Review Articles, Minireviews and Commentaries are either invited by the Editors or may be submitted for consideration. Authors who wish to contribute a manuscript to one of these categories should contact the Editor-in-Chief.

Review Articles describe new developments of interdisciplinary significance and highlight unresolved questions and future directions. They do not generally occupy more than 9 printed pages.

Minireviews should focus on topics of current interest and not exceed 5 printed pages.

Commentaries should offer a more personalized perspective on a topic that will be of interest to the general readership and fill an integral number of printed pages, generally one or two, including one or two small figures. All contributions to these categories will be subjected to editorial review.

Reports should comprise title page, Key Words, Abstract, Introduction, Results and Discussion, References, tables, figure legends, and figures – in this order.



Conditions

Only manuscripts that conform to the Guidelines for Authors will be considered and are subject to editorial review.

The manuscript must be accompanied by a cover letter stating that all authors have seen and given their approval for submission of the manuscript to be considered for publication in Neurodegenerative Diseases. Manuscripts are accepted for review with the understanding that persons cited in unpublished work have approved such citations. Authors are required to identify a minimum of four preferred reviewers.

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication or have not already been published elsewhere. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Neurodegenerative Diseases and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

For legal reasons, we must receive your 'Submission Statement' with your original (hand-written) signature. Please download, print, sign and either fax or scan it to make it legally binding.

The authors agree that their articles will be accompanied, if necessary, by a simplified version written by a scientific writer.

Manuscripts that do not comply with the ethical standards recommended by the Helsinki Declaration will not be accepted.



Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).



Arrangement

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone/fax numbers and e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of about 200 words, and should be structured as follows:
   Background: What prompted the study?
   Objective: What is the purpose of the study?
   Methods: How was the study carried out?
   Results: What are the most important findings?
   Conclusion: What is the most important conclusion?

The abstract should not exceed 250 words, and any abbreviations must be explained.

Footnotes: Avoid footnotes. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figure legends should be supplied on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs will be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author's name, and 'top' with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, and line drawings one of 800–1,200 dpi.



Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00.



References

Identify references in the text with Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by their initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(a) Papers published in periodicals:
Desai MY, De la Peña-Almaguer E, Mannting F: Abnormal heart rate recovery after exercise: A comparison with known indicators of increased mortality. Cardiology 2001;96:38–44.
Hadler, W.A., S.R. Silveira (1981) Técnica histoquímica que permite iscriminar o colesterol de substâncias afins e de seus ésteres. Cienc Cult 33(suppl): 586–587.

(b) Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Books:
Matheis G, Moritz A, Scholz M (eds): Leukocyte Depletion in Cardiac Surgery and Cardiology. Basel, Karger, 2002.

(d) Edited books:
Gladish GW, Haponik EF: Virtual Bronchoscopy; in Bolliger CT, Mathur PM (eds): Interventional Bronchoscopy. Prog Respir Res. Basel, Karger, 2000, vol 30, pp 253–266.


Papers that have been submitted but are not yet accepted should not be listed in the bibliography, but can be referred to in the text as unpublished observations. If details of methods are only available in papers that are 'in press', copies of the papers should be included with the manuscript submitted to Neurodegenerative Diseases so that the editorial referees can have adequate information to judge the manuscript.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.



Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org



Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.



Drugs

Generic names should be used in text, tables, and figures. Trade names in upper case may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. The chemical nature of new drugs must be given when known.



Abbreviations

When an abbreviation is used in the manuscript, it should be defined in the text the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs/chemicals may be used if properly defined with the chemical or generic name when the abbreviation is first used. Excessive use of abbreviations in the text, however, is strongly discouraged. Most abbreviations are used without punctuation, with no distinction between singular and plural forms.



Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.


Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.


Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.




Page Charges

There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 14 manuscript pages (including tables, illustrations and references).



E-pub First

All articles are published electronically ahead of print with a DOI number and are supplemented later with te definite reference of the printed version. The articles become available immediately after the authors' approval to publication, with the added advantage of being citable much earlier than previously. Authors can influence the time of appearance by promptly returning the proofs.



Proofs

Unless otherwise indicated, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.



Reprints

Order forms and a price list will be sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.